{"result": "(\"entity\"<|>ASOCIACIÓN EUROPEA DE NUTRICIÓN ENTERAL Y PARENTERAL<|>ORGANIZATION<|>The European Society for Clinical Nutrition and Metabolism (ESPEN) provides guidelines on enteral and parenteral nutrition for patients, particularly in oncology settings.)\n##\n(\"entity\"<|>PACIENTE ONCOLÓGICO<|>PERSON<|>An adult cancer patient who may require nutritional support during treatment.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition refers to the delivery of nutrients directly into the gastrointestinal tract, often used for patients who cannot eat normally.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Parenteral nutrition is the intravenous administration of nutrients, typically used when enteral feeding is not possible or sufficient.)\n##\n(\"entity\"<|>MALNUTRICIÓN<|>EVENT<|>Malnutrition refers to a condition that results from an unbalanced diet or inability to absorb nutrients, which is a concern for cancer patients.)\n##\n(\"entity\"<|>SUPLEMENTOS NUTRICIONALES<|>EVENT<|>Nutritional supplements are products taken to enhance dietary intake, particularly important for patients with specific nutritional needs.)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>NUTRICIÓN ENTERAL<|>Cancer patients may require enteral nutrition if they cannot meet their nutritional needs through oral intake.<|>8)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>NUTRICIÓN PARENTERAL<|>Cancer patients may require parenteral nutrition when enteral feeding is not possible or sufficient.<|>8)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>MALNUTRICIÓN<|>Cancer patients are at risk of malnutrition due to their condition and treatment side effects.<|>9)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>SUPLEMENTOS NUTRICIONALES<|>Cancer patients may need nutritional supplements to meet their dietary requirements during treatment.<|>7)\n##\n(\"relationship\"<|>ASOCIACIÓN EUROPEA DE NUTRICIÓN ENTERAL Y PARENTERAL<|>NUTRICIÓN ENTERAL<|>ESPEN provides guidelines for the use of enteral nutrition in cancer patients.<|>6)\n##\n(\"relationship\"<|>ASOCIACIÓN EUROPEA DE NUTRICIÓN ENTERAL Y PARENTERAL<|>NUTRICIÓN PARENTERAL<|>ESPEN offers recommendations for the use of parenteral nutrition in clinical settings, including oncology.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: carcinoma-\ntosis peritoneal o resecciones intestinales, se deberá utili-\nzar la vía parenteral. En general, los riesgos de la nutrición\nparenteral superan su beneficio en pacientes con un pro-\nnóstico vital inferior a 2 meses, por lo que se debe sopesar\ncuidadosamente su indicación en pacientes terminales.\n\nLa vía de nutrición enteral dependerá de la situación\nclínica y la patología de base del paciente. De modo\nrutinario, se siguen los algoritmos para la población\n\ngeneral. Optando por accesos permanentes (gastrosto-\nmía, yeyunostomía), cuando tengamos que prolongar\nel soporte nutricional más allá de las 4-6 semanas. Pero\nexisten situaciones clínicas presentes en estos pacientes\nque pueden requerir la realización temprana de un ac-\nceso enteral (disfagia mecánica, mucositis), en ocasio-\nnes sin haber utilizado previamente SNG o colocar ac-\ncesos permanentes profilácticos, por ejemplo, en un\npaciente que pueda presentar mucositis o que tenga\nun tumor no operable cuyo crecimiento impida la utili-\nzación del tracto digestivo superior.\n\nAunque existe debate sobre las indicaciones para co-\nmenzar el soporte nutricional en los pacientes oncológi-\ncos, en general, la práctica clínica, las contraindicacio-\nnes, las complicaciones y la monitorización del soporte\nnutricional no difieren de los pacientes con patología\nbenigna. Sí hay que tener en cuenta los aspectos éticos\nde prolongar el soporte nutricional hasta el final de la\nvida. Pero debemos sopesar las posibles complicaciones\ny la falta de eficacia del tratamiento frente a las ventajas\nfisiológicas o psicológicas que pueda aportar a un deter-\nminado paciente o a su familia31.\n\n6.5.1. Suplementos orales\n\nIndicados en pacientes que cubren al menos el 60%\nde sus necesidades con la alimentación tradicional.\n\nNo existen datos que apoyen el uso de suplementos\nespecíficos para pacientes oncológicos, por lo que, en\ngeneral, se pueden prescribir las fórmulas estándar. La\nexcepción son aquellos pacientes que vayan a ser some-\ntidos a tratamiento quirúrgico. En estos, las fórmulas\nenriquecidas con arginina y otros inmunonutrientes,\nhan demostrado beneficios adicionales32, aunque los es-\ntudios se han realizado con soporte enteral, por lo que\nla fórmula constituiría la principal fuente alimentaria.\n\nPara aquellos pacientes con hiporexia o sensación de\nsaciedad precoz, los suplementos más adecuados se-\nrían los de elevada densidad calórica (≥ 1,5 kcal/ml) e\nhiperproteicos. Estos deben administrarse de forma\nque no disminuyan el apetito del paciente en las comi-\ndas principales, por lo que resulta útil tomarlos entre\nellas y antes de acostarse.\n\n6.5.2. Nutrición enteral\n\nNo existe evidencia que apoye la utilización de NE\nen pacientes normonutridos que vayan a ser someti-\ndos a quimioterapia, radioterapia o trasplante de mé-\ndula ósea32. Sin embargo, existe debate con la actitud\na seguir en los pacientes oncológicos que se vayan a\nsometer a cirugía abdominal mayor:\n\n• La Asociación Europea de Nutrición Enteral y Paren-\nteral (ESPEN) recomienda la administración de NE\npreoperatoria durante 5-7 días, preferiblemente\ncon inmunonutrientes (arginina, ácidos grasos ω-3\n---\n648      BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\n| Paciente oncológico adulto |\n|----------------------------|\n| ¿Posibilidad de terapia oncológica? |\n| SÍ |\n| Valoración nutricional |\n\n| NO |\n|-----|\n| Algoritmo de paliativos |\n\n| Normonutrido (A) | Malnutrición moderada o riesgo de malnutrición (B) | Malnutrición grave (C), independientemente del tipo de tratamiento |\n|-------------------|---------------------------------------------------|----------------------------------------------------------------------|\n\n| Terapia de bajo riesgo | Terapia de riesgo moderado | Terapia de alto riesgo | Terapia de bajo riesgo | Terapia de riesgo moderado | Terapia de alto riesgo |\n|------------------------|----------------------------|------------------------|------------------------|----------------------------|------------------------|\n\n| · Educación nutricional básica | · Recomendaciones dietéticas específicas | · Recomendaciones dietéticas específicas | · Nutrición enteral |\n| · Recomendaciones dietéticas generales | · Control de síntomas | · Control de síntomas | o |\n| · Control de síntomas | | · Dieta hiperproteica | · Nutrición parenteral |\n| | · Recomendaciones dietéticas específicas | · Suplementos nutricionales |\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}